A
Class-leading
Injectable division · Amylin + GLP-1 combo
CagriSema
Novo Nordisk · once weekly
Certified
Division standing
#3 of 5
Injectable division
← Tolerability cost (bands)% body weight lost →
Mild017% vs placebo
Tolerability: the cost
Mild6% vs 3.7% placebo
AE-discontinuation +2.3 points, at the 2.4 mg / 2.4 mg weekly. From REDEFINE-1.
Efficacy
17%2.4 mg / 2.4 mg · placebo-adjusted · 68 wk
REDEFINE-1: 20.4% vs 3% placebo, a 17-point gap on the treatment policy estimand.
Frontier-level loss with mild tolerability: the gentlest of the class leaders.
NDA submitted; not yet approved.
Convenience profile: you weigh it, not us
Route
Subcutaneous injection
Frequency
Once weekly
Food / water rule
None
Titration
Multi-step escalation of both components
Storage
Refrigerated
Provenance: every number traces back
TrialREDEFINE-1 · NCT05567796
Estimandtreatment policy estimand
Populationnon-diabetic obesity
Dose2.4 mg / 2.4 mg weekly
SourceNEJM 2025
Verdict confirmed5 Jul 2026
Next milestone: FDA decision on the submitted NDAMechanism field guide →